Key takeaways

  • XRF Scientific (ASX:XRF) agreed to acquire the Combustion Gas Analysis (CGA) business of Bruker AXS SE, adding a suite of carbon/sulphur and oxygen/hydrogen/nitrogen (CS/OHN) elemental analysers to its portfolio.
  • The transaction was announced on 23 April 2026 and structured as an upfront payment of USD 4.0 million from existing cash reserves, plus an earnout of up to USD 1.0 million over three years tied to 7% of net CGA revenue.
  • The upfront consideration represented roughly 0.75 times the CGA business's 2025 unaudited revenue of about USD 5.3 million.
  • Shares in the company were trading up 3.0% at A$2.85 on 23 July 2026.
  • For the quarter to March 2026, XRF reported revenue of AUD 15.8 million (up 13.8% year-on-year) and profit before tax of AUD 3.7 million (up 10.7%).

XRF Scientific Limited (ASX:XRF) is a Western Australia-based supplier of fusion equipment, laboratory consumables and scientific instruments, serving mining, cement, glass and other industrial sectors globally. The company recently completed the acquisition of the Combustion Gas Analysis (CGA) business from Bruker AXS SE, paying USD 4.0 million upfront with a USD 1.0 million earnout payable over three years, in a deal announced on 23 April 2026. Shares in XRF Scientific were trading up 3.0% at A$2.85 on 23 July 2026. The CGA product line — which includes analysers used across industrial sectors including oil and gas, cement and metals — broadens XRF's offering beyond its core mining-laboratory customer base and adds an established manufacturing operation in Karlsruhe, Germany, which the company intends to transition to its own facilities over time.

The acquisition: what XRF Scientific announced

On 23 April 2026, XRF Scientific announced an agreement to acquire the Combustion Gas Analysis (CGA) business from Bruker AXS SE, part of the global scientific-instruments group Bruker. The CGA business supplies a range of CS/OHN elemental analysers — instruments used to measure carbon, sulphur, oxygen, hydrogen and nitrogen content in materials. These analysers are applied across a variety of industrial sectors that extend beyond the mining and minerals markets XRF has traditionally served.

Under the terms disclosed, XRF agreed to pay USD 4.0 million upfront, funded from existing cash reserves, with an additional earnout of up to USD 1.0 million payable over three years. That earnout is calculated as 7% of the net revenue generated by the CGA business over the period. The upfront consideration equated to approximately 0.75 times the CGA business's 2025 unaudited revenue of around USD 5.3 million.

The company indicated that the transaction carried no conditions precedent and was expected to complete in the week of the announcement. As part of the deal, key sales-management and technical-support employees from Bruker's operations in Germany and the United States were expected to transition to XRF, helping to preserve customer relationships and specialist technical knowledge through the handover.

Financial and operational details

The CGA product line has historically been manufactured in Karlsruhe, Germany. XRF signalled its intention to transition manufacturing to its facilities in Perth, Western Australia, with that shift anticipated during the third quarter of the 2026 calendar year. Reflecting the time required to relocate production and integrate the business, XRF indicated that it did not expect the acquisition to begin generating revenue for the group until the fourth quarter of 2026.

The strategic logic put forward centred on diversification and cross-selling. By adding combustion-based elemental analysers, XRF broadens its instrument offering into non-mining industrial markets while creating potential to sell CGA instruments alongside its existing product range — and, importantly, to build recurring consumable and service revenue streams associated with the installed base of analysers.

The acquisition arrived against a backdrop of solid trading. For the quarter ended March 2026, XRF reported revenue of AUD 15.8 million, an increase of 13.8% year-on-year, and profit before tax of AUD 3.7 million, up 10.7% on the prior corresponding period. The company also described maintaining a healthy net-cash position and positive operating cash flow, which is consistent with funding the upfront consideration from existing reserves rather than raising new capital or taking on debt.

By way of background, XRF Scientific is headquartered in Osborne Park, Western Australia, and has been listed on the ASX since October 2006. Its established operations span fusion equipment, laboratory consumables and fluxes, precious-metal (platinum) labware, and analytical instruments, serving customers in mining, metals and broader materials-analysis applications internationally.

Potential opportunities and positive factors

Several aspects of the transaction may be viewed constructively by investors. First, the acquisition diversifies XRF's revenue base beyond mining-laboratory markets into wider industrial applications, potentially reducing the company's sensitivity to any single end-market. Second, the deal was funded from existing cash, avoiding dilution to shareholders or an increase in gearing. Third, the retention of experienced sales and technical staff from Bruker's German and US operations may smooth the integration and help protect existing customer relationships.

The consumable and service dimension is also notable. Analytical instruments of this type typically generate ongoing demand for consumables, spare parts and support, which can create recurring, higher-margin revenue over the life of an installed instrument. Combined with cross-selling potential across XRF's existing customer network, this could support the company's long-term earnings profile if execution goes to plan. The modest headline multiple of roughly 0.75 times the target's 2025 revenue suggests XRF sought to acquire the business on disciplined terms.

Material risks, uncertainties and investor considerations

Against these opportunities sit several risks. The most immediate is integration and manufacturing-transition risk: relocating production of a specialised instrument line from Karlsruhe, Germany to Perth is a complex undertaking, and any disruption could delay revenue or add cost. XRF itself flagged that the acquisition was not expected to contribute revenue until the fourth quarter of 2026, underscoring the lead time involved.

Retention of the transitioning Bruker personnel is not guaranteed, and the loss of key staff could erode the technical know-how and customer goodwill the deal is designed to preserve. The earnout structure ties additional payments to CGA revenue performance, which introduces some uncertainty around total consideration, though it also aligns cost with realised sales. Currency exposure is another factor, given the purchase price is denominated in US dollars while XRF reports in Australian dollars.

What investors may watch next

Key milestones to monitor include confirmation that the CGA manufacturing transition to Perth has been completed on schedule, and evidence that the acquired business begins contributing revenue from the fourth quarter of 2026 as guided. Investors may also look for commentary in XRF's subsequent quarterly and full-year results on how the CGA integration is progressing, the pace of any cross-selling, and the development of recurring consumable revenue. Updates on staff retention, order intake for the analysers, and the company's overall cash position and dividend policy will likewise be relevant in assessing whether the acquisition is delivering the intended benefits.

Conclusion